Hikma Pharmaceuticals (LON:HIK) Shares Down 14.1% After Analyst Downgrade

Hikma Pharmaceuticals PLC (LON:HIK)’s share price dropped 14.1% during trading on Thursday after Berenberg Bank lowered their price target on the stock from GBX 2,510 to GBX 2,300. Berenberg Bank currently has a buy rating on the stock. Hikma Pharmaceuticals traded as low as GBX 1,522 and last traded at GBX 1,522. Approximately 166,325,172 shares were traded during trading, an increase of 7,989% from the average daily volume of 2,056,107 shares. The stock had previously closed at GBX 1,771.

A number of other analysts have also commented on HIK. JPMorgan Chase & Co. decreased their price objective on Hikma Pharmaceuticals from GBX 2,500 to GBX 2,400 and set an “overweight” rating for the company in a report on Friday. Peel Hunt restated a “buy” rating and set a GBX 2,170 price objective on shares of Hikma Pharmaceuticals in a research note on Friday. Deutsche Bank Aktiengesellschaft dropped their target price on shares of Hikma Pharmaceuticals from GBX 3,100 to GBX 2,850 and set a “buy” rating on the stock in a research report on Tuesday, August 12th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a GBX 2,360 price target on shares of Hikma Pharmaceuticals in a report on Friday. Five analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of GBX 2,416.

Insider Activity

In other Hikma Pharmaceuticals news, insider Laura Balan Balan bought 3,500 shares of Hikma Pharmaceuticals stock in a transaction dated Friday, August 22nd. The stock was acquired at an average cost of GBX 1,821 per share, for a total transaction of £63,735. Also, insider Mazen Darwazah purchased 315,000 shares of the company’s stock in a transaction dated Thursday, November 6th. The stock was bought at an average price of GBX 1,601 per share, with a total value of £5,043,150. Over the last quarter, insiders purchased 332,500 shares of company stock worth $533,130,500. 17.77% of the stock is currently owned by insiders.

Hikma Pharmaceuticals Stock Performance

The stock has a market capitalization of £3.50 billion, a PE ratio of 9.47, a P/E/G ratio of 2.38 and a beta of 0.41. The company has a debt-to-equity ratio of 55.82, a quick ratio of 1.27 and a current ratio of 1.66. The firm’s 50 day moving average is GBX 1,730.88 and its two-hundred day moving average is GBX 1,893.97.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.